Levofloxacin Can Greatly Influence Clinical Practice of Cancer Treatment: It Has Broad-Spectrum Anticancer Activity and Synergistically Enhance Conventional Chemotherapy

2019 ◽  
Author(s):  
Xiaoqiong He ◽  
Qian Yao ◽  
Zhong Yu Song ◽  
Dan Fan ◽  
Yu Tong You ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Cancer Treatment ◽  
Anticancer Activity ◽  
Broad Spectrum ◽  
Conventional Chemotherapy

Design of Lamivudine Loaded Nanoparticles for Oral Application by Nano Spray Drying Method: A New Approach to use an Antiretroviral Drug for Lung Cancer Treatment

2020 ◽  
Vol 23 (10) ◽  
pp. 1064-1079
Author(s):  
Ahmet Alper Öztürk ◽  
İrem Namlı ◽  
Kadri Güleç ◽  
Şennur Görgülü
Keyword(s):  
Lung Cancer ◽  
Cancer Treatment ◽  
Anticancer Activity ◽  
Cell Line ◽  
Anticancer Drugs ◽  
Release Kinetics ◽  
Prolonged Release ◽  
Lung Cancer Treatment ◽  
Anticancer Properties ◽  
Ft Ir

Aims: To prepare lamivudine (LAM)-loaded-nanoparticles (NPs) that can be used in lung cancer treatment. To change the antiviral indication of LAM to anticancer. Background: The development of anticancer drugs is a difficult process. One approach to accelerate the availability of drugs is to reclassify drugs approved for other conditions as anticancer. The most common route of administration of anticancer drugs is intravenous injection. Oral administration of anticancer drugs may considerably change current treatment modalities of chemotherapy and improve the life quality of cancer patients. There is also a potentially significant economic advantage. Objective: To characterize the LAM-loaded-NPs and examine the anticancer activity. Methods: LAM-loaded-NPs were prepared using Nano Spray-Dryer. Properties of NPs were elucidated by particle size (PS), polydispersity index (PDI), zeta potential (ZP), SEM, encapsulation efficiency (EE%), dissolution, release kinetics, DSC and FT-IR. Then, the anticancer activity of all NPs was examined. Results: The PS values of the LAM-loaded-NPs were between 373 and 486 nm. All NPs prepared have spherical structure and positive ZP. EE% was in a range of 61-79%. NPs showed prolonged release and the release kinetics fitted to the Weibull model. NPs structures were clarified by DSC and FT-IR analysis. The results showed that the properties of NPs were directly related to the drug:polymer ratio of feed solution. NPs have potential anticancer properties against A549 cell line at low concentrations and non-toxic to CCD 19-Lu cell line. Conclusion: NPs have potential anticancer properties against human lung adenocarcinoma cells and may induce cell death effectively and be a potent modality to treat this type of cancer. These experiments also indicate that our formulations are non-toxic to normal cells. It is clear that this study would bring a new perspective to cancer therapy.

Anticancer Activity of Diosgenin and its Semi-synthetic Derivatives: Role in Autophagy Mediated Cell Death and Induction of Apoptosis

2021 ◽  
Vol 21 ◽  
Author(s):  
Nivedita Bhardwaj ◽  
Nancy Tripathi ◽  
Bharat Goel ◽  
Shreyans K. Jain
Keyword(s):  
Cell Death ◽  
Cancer Treatment ◽  
Anticancer Activity ◽  
Tumor Cells ◽  
Cancer Progression ◽  
Rational Approach ◽  
Potential Candidate ◽  
Potential Implication ◽  
Apoptosis Protein ◽  
Synthetic Derivatives

: During cancer progression, the unrestricted proliferation of cells is supported by the impaired cell death response provoked by certain oncogenes. Both autophagy and apoptosis are the signaling pathways of cell death, which are targeted for cancer treatment. Defects in apoptosis result in reduced cell death and ultimately tumor progression. The tumor cells lacking apoptosis phenomena are killed by ROS- mediated autophagy. The autophagic programmed cell death requires apoptosis protein for inhibiting tumor growth; thus, the interconnection between these two pathways determines the fate of a cell. The cross-regulation of autophagy and apoptosis is an important aspect to modulate autophagy, apoptosis and to sensibilise apoptosis-resistant tumor cells under metabolic stress and might be a rational approach for drug designing strategy for the treatment of cancer. Numerous proteins involved in autophagy have been investigated as the druggable target for anticancer therapy. Several compounds of natural origin have been reported, to control autophagy activity through the PI3K/Akt/mTOR key pathway. Diosgenin, a steroidal sapogenin has emerged as a potential candidate for cancer treatment. It induces ROS-mediated autophagy, inhibits PI3K/Akt/mTOR pathway, and produces cytotoxicity selectively in cancer cells. This review aims to focus on optimal strategies using diosgenin to induce apoptosis by modulating the pathways involved in autophagy regulation and its potential implication in the treatment of various cancer. The discussion has been extended to the medicinal chemistry of semi-synthetic derivatives of diosgenin exhibiting anticancer activity.

scholarly journals Carbohydrate-Based NK1R Antagonists with Broad-Spectrum Anticancer Activity

2021 ◽  
Author(s):  
Rocío Recio ◽  
Patricia Lerena ◽  
Esther Pozo ◽  
José Manuel Calderón-Montaño ◽  
Estefanía Burgos-Morón ◽  
...  
Keyword(s):  
Anticancer Activity ◽  
Broad Spectrum

Predictive Modeling for Adverse Events and Risk Stratification Programs for People Receiving Cancer Treatment

2021 ◽  
pp. OP.21.00198
Author(s):  
Chelsea K. Osterman ◽  
Hanna K. Sanoff ◽  
William A. Wood ◽  
Megan Fasold ◽  
Jennifer Elston Lafata
Keyword(s):  
Clinical Practice ◽  
Risk Stratification ◽  
Cancer Treatment ◽  
Acute Care ◽  
Predictive Modeling ◽  
Predictive Models ◽  
Emergency Department Visits ◽  
Targeted Interventions ◽  
Risk Algorithm ◽  
Oncology Care

Emergency department visits and hospitalizations are common among people receiving cancer treatment, accounting for a large proportion of spending in oncology care and negatively affecting quality of life. As oncology care shifts toward value- and quality-based payment models, there is a need to develop interventions that can prevent these costly and low-value events among people receiving cancer treatment. Risk stratification programs have the potential to address this need and optimally would consist of three components: (1) a risk stratification algorithm that accurately identifies patients with modifiable risk(s), (2) intervention(s) that successfully reduce this risk, and (3) the ability to implement the risk algorithm and intervention(s) in an adaptable and sustainable way. Predictive modeling is a common method of risk stratification, and although a number of predictive models have been developed for use in oncology care, they have rarely been tested alongside corresponding interventions or developed with implementation in clinical practice as an explicit consideration. In this article, we review the available published predictive models for treatment-related toxicity or acute care events among people receiving cancer treatment and highlight challenges faced when attempting to use these models in practice. To move the field of risk-stratified oncology care forward, we argue that it is critical to evaluate predictive models alongside targeted interventions that address modifiable risks and to demonstrate that these two key components can be implemented within clinical practice to avoid unplanned acute care events among people receiving cancer treatment.

Levofloxacin exerts broad-spectrum anticancer activity via regulation of THBS1, LAPTM5, SRD5A3, MFAP5 and P4HA1

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Xiaoqiong He ◽  
Qian Yao ◽  
Duane D Hall ◽  
Zhongyu Song ◽  
Dan Fan ◽  
...  
Keyword(s):  
Anticancer Activity ◽  
Broad Spectrum

scholarly journals Consensus Recommendations From the Children’s Oncology Group Nursing Discipline’s State of the Science Symposium: Symptom Assessment During Childhood Cancer Treatment

2019 ◽  
Vol 36 (4) ◽  
pp. 294-299
Author(s):  
Janice S. Withycombe ◽  
Maureen Haugen ◽  
Sue Zupanec ◽  
Catherine F. Macpherson ◽  
Wendy Landier
Keyword(s):  
Clinical Practice ◽  
Cancer Treatment ◽  
Childhood Cancer ◽  
Symptom Assessment ◽  
Self Report ◽  
Oncology Group ◽  
Symptom Trajectories ◽  
Science Symposium ◽  
State Of The Science ◽  
Core Symptoms

Background: Recognizing and addressing illness-related distress has long been a priority for pediatric oncology nurses and the Children’s Oncology Group. Although symptoms are known to be highly prevalent during treatment for childhood cancer, there is currently no guidance for how often symptoms should be assessed, which symptoms should be prioritized for assessment, and how the data should be collected. Methods: The Nursing Discipline, within Children’s Oncology Group, hosted a one-day Interprofessional seminar titled “Symptom Assessment During Childhood Cancer Treatment: State of the Science Symposium.” Following the symposium, an expert panel was assembled to review all available evidence, including information presented and collected during the symposium. Consensus-building discussions were held to identify common themes and to produce recommendations for clinical practice. Results: Four recommendations emerged including (1) the identification of priority “core” symptoms for assessment; (2) inclusion of the child’s voice through self-report, when possible; (3) consistent documentation and communication of symptom assessment results; and (4) implementation of patient/family education related to symptoms. Discussion: Symptom recognition, through appropriate assessment, is the first step in symptom management. The goal for developing and sharing these recommendations is to promote consistent and comparable clinical practice across institutions in regard to symptom assessment during childhood cancer therapy. Integration of these recommendations will set the stage for future studies related to the frequency of symptoms across disease groups, projection of anticipated symptom trajectories, development of evidence-based teaching tools for common symptoms, and evaluation of patient outcomes with enhanced symptom assessment and management.

One-hour test for estimating intestinal absorption of calcium by using stable strontium as a marker

1994 ◽  
Vol 40 (2) ◽  
pp. 257-259 ◽  
Author(s):  
A J Sips ◽  
J C Netelenbos ◽  
R Barto ◽  
P Lips ◽  
W J van der Vijgh
Keyword(s):  
Clinical Practice ◽  
Intestinal Absorption ◽  
Broad Spectrum ◽  
Calcium Metabolism ◽  
Calcium Absorption ◽  
Area Under The Curve ◽  
Close Correlation ◽  
Reliable Information ◽  
Simple Test ◽  
Stable Strontium

Abstract Intestinal absorption of calcium is a relevant marker in a broad spectrum of diseases; however, its determination in clinical practice is difficult. Our aim was to design a simple test for this based on stable strontium (88Sr). The correlation between the intestinal absorption of simultaneously administered 45Ca and 88Sr was investigated in patients with various disorders of the bone and calcium metabolism. The area under the curve for the period 0-60 min after dosing (AUC0-60 in mmol.L-1.min), being a representative measure of intestinal absorption, showed a close correlation between both elements (r = 0.90, P < 0.001). Moreover, the measure of agreement in classifying the patients as low, intermediate, or high absorbers was high (kappa = 0.80). We conclude that a test based on measuring AUC0-60 of strontium is a fast and inexpensive way to obtain reliable information about the level of intestinal calcium absorption.

Sign in / Sign up

Export Citation Format

Share Document